The deal adds a blood-based test for viral-mediated cancers to the company’s portfolio of transplant and cell therapy services.
CareDx has completed its acquisition of Naveris, a company specializing in specialty oncology diagnostics. The transaction, following the satisfaction of all closing conditions, expands CareDx’s services into viral-mediated cancer testing.
Naveris’s lead product, NavDx, is a blood-based test that detects and monitors viral-mediated cancers, including human papillomavirus (HPV)-associated head and neck and anal cancers. The test is used from the point of diagnosis through post-treatment molecular residual disease (MRD) surveillance. NavDx is the only Medicare-covered assay for HPV-driven head and neck and anal cancer MRD, according to the company.
“CareDx wins by commercializing category-leading, repeat molecular biomarker testing for patients with a high burden of disease—that’s our growth model,” says John Hanna, president and CEO of CareDx, in a release. “NavDx fits that model precisely. We believe we have the platform and the focus to scale it, and we expect it to be a meaningful contributor to CareDx’s growth from day one.”
More than 130,000 NavDx tests have been commercially reported to date. The test obtained Medicare coverage in 2023 and has an advanced diagnostic laboratory test Medicare reimbursement rate of $1,800.
The acquisition allows CareDx to offer diagnostic testing services across solid organ transplant, cell therapy-based hematologic malignancies, and viral-mediated cancers. The company estimates the US market for these areas exceeds $12 billion.
CareDx will include Naveris in its consolidated financial results beginning in the third quarter of 2026.
ID 60933364 © Pichetw | Dreamstime.com
